– USA, CO – Greyledge Technologies, Inc. announced the appointment of James Johnston, an innovative executive with extensive financial and strategic experience with global organizations, and Chief of Corporate Development for Greyledge since last fall, to its board of directors.
His extensive network of contacts, diverse strategic abilities, and extensive experience in investment banking and private equity will continue to facilitate the cell therapeutics company’s growth strategy while maintaining its commitment to quality standards.
“Mr. Johnston has been an instrumental member of the Greyledge team in his role as Chief of Corporate Development and we are thrilled to appoint him to the board. Jim is a seasoned leader and, as Greyledge continues to accelerate efforts to scale our novel cellular therapeutics platform in domestic and international markets. He will be a vital asset to access additional growth capital and provide comprehensive strategic guidance,” said founder and CEO, Dr. David Karli.
About James Johnston
James Johnston has spent 22 years advising and investing in companies across a variety of industries. He brings expertise in financing, mergers and acquisitions, strategic execution, and board-level decision-making. Jim was an investment banker at Goldman Sachs from 2000-2008 in Mergers and Acquisitions and Financial Sponsor Coverage. He joined Nexphase Capital Partners in 2008 and ultimately ran the Industrials Group as a Partner. In 2018, Mr. Johnston left Nexphase and founded Emerald Lake Advisors to focus his energy on investing and advising small entrepreneurial companies.
Mr. Johnston serves on the board of directors of the Red Fox Community School and as a board observer of Jame Rollform Products. He received a BS in Commerce with Distinction from the University of Virginia in 1991 and was commissioned as a Naval Officer through the ROTC program. After graduating from Nuclear Power School and Prototype he served as a submarine officer and is a qualified Naval Nuclear Engineer. After his separation from the Navy, he received his MBA from Harvard Business School in 2000.
About Greyledge, Inc.
Founded in 2010 in Colorado, Greyledge is an industry-leading biotech company specializing in cell therapeutics produced from a patient’s blood or bone marrow. Greyledge has developed industry-leading quality control systems to process these biological therapy products, used in treating common Orthopedic conditions. The Company is dedicated to maximizing product quality, safety, and reliability in a manner compliant with Federal regulations and ethical standards. The Company has refined its scientific technology, and since 2017, has been driven to achieve sustained profitability and scalability.
For more information: https://www.greyledgebiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.